EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Floor Dysfunction
BTXA EMG
A Pilot Study: Botulinum Toxin Type A Injections Into Pelvic Muscles for Patients With Refractory High Tone Pelvic Floor Dysfunction
1 other identifier
interventional
28
1 country
1
Brief Summary
This is a prospective, pilot, longitudinal study to evaluate the use of EMG guidance for Botox A injection for chronic pelvic pain and HTPFD. The objective of this study is to determine the efficacy of injecting botulinum toxin type A into pelvic floor muscles that are high tone. Patients who have been diagnosed with high tone pelvic floor muscle dysfunction and have failed other treatments will be eligible to participate in this study. Study related procedures will include perineometry readings. Patients will be required to complete 7 questionnaires for this study. These include visual analog scale (scale from 0-10) for pain (VAS), the O'Leary-Sant urinary symptoms and problem questionnaires (ICSI/ICPI), Pelvic Floor Distress Inventory 20 (PFDI-20), the Female Sexual Distress Scale (FSDS), Global Response Assessment Scale and the SF-12 quality of life scale. The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections. This is a prospective, pilot, longitudinal study to evaluate the effect of Botox A injection for chronic pelvic pain and HTPFD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2010
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2010
CompletedFirst Submitted
Initial submission to the registry
March 24, 2011
CompletedFirst Posted
Study publicly available on registry
March 28, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedMay 5, 2014
May 1, 2014
2.7 years
March 24, 2011
May 2, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To evaluate the use of EMG guidance for Botox A injection for chronic pelvic pain and HTPFD.
6 months
Interventions
The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
Eligibility Criteria
You may qualify if:
- Participant must be diagnosed with High Tone Pelvic Floor Dysfunction(HTPMFD).
- Participant must have tried and failed at least one other conventional mode of therapy for HTPMFD.
- Participant must be a female at least 18 years of age.
- Participant must give written informed consent to participate in this study.
- Participant must be able to make decisions for herself.
- Participant must not be undergoing another procedure at the time of BTX A injection.
You may not qualify if:
- Participant is male.
- Patient has a history of past BTX A use
- Patient has had pelvic organ prolapse repair
- Participant is pregnant or intends to get pregnant during the study period or is breastfeeding.
- Participant is unwilling or unable (because of long distance from office) to follow-up.
- Participant has a neuro-modulator device implanted.
- Participant has a known bleeding disorder or is on anticoagulation.
- Participant has a known hypersensitivity to BTX A.
- Participant has a pre-existing neuromuscular disorder such as amytrophic lateral sclerosis, motor neuropathy, myasthenia gravis or Lambert-Eaton syndrome.
- Participant with skin infection at the perineum at the site of injection.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pelvic and Sexual Health Institutelead
- Allergancollaborator
Study Sites (1)
Pelvic and Sexual Health Institute
Philadelphia, Pennsylvania, 19107, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Kristene E Whitmore, MD
Pelvic and Sexual Health Institute
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical Director
Study Record Dates
First Submitted
March 24, 2011
First Posted
March 28, 2011
Study Start
November 1, 2010
Primary Completion
July 1, 2013
Study Completion
December 1, 2013
Last Updated
May 5, 2014
Record last verified: 2014-05